Multiple Myeloma an incurable disease, but I have spent the last 25 years in remission using a blend of conventional oncology and evidence-based nutrition, supplementation, and lifestyle therapies from peer-reviewed studies that your oncologist probably hasn't told you about.
Click the orange button to the right to learn more about what you can start doing today.
You’ve been diagnosed with multiple myeloma. Naturally you’re wondering about which therapies will work the best for you. Low-dose maintenance therapy has been shown to increase progression-free survival (PFS) but not overall survival (OS) consistently.
PFS means your first remission. But not an increase in OS aka overall survival. When it comes to myeloma survival, only low-dose maintenance therapy, on average, increases your first remission.
Low-dose maintenance therapy will increase your risk of side effects an probably lower your quality-of-life.
Being a long-term MM survivor who hasn’t had toxic therapies of any kind since 1997, I consider it my responsibility to think about conventional MM differently than how your oncologist thinks about therapy.
Take the issue in the study linked and excerpted below. I have to question if the issue is not if Revlimid (lenalidomide) is the reason for increased overall survival in multiple myeloma (MM), but if the issue is whether or not low-dose maintenance therapy is the reason for increases in overall survival in multiple myeloma.
What I mean by the above statement is that my research and personal myeloma experience is that hitting MM daily with apoptotic therapies is the reason why I have remained in complete remission from my MM since my complete remission in 4/99.
There are three known facts about low-dose Revlimid maintenance therapy:
Many different types of anti-angiogeneic therapies have been proven to kill MM. Whether it is in the form of chemotherapy like Revlimid, Thalidomide, Curcumin, or even cannabinoids. Antiangiogenesis kills MM.
Revlimid causes a host of side effects listed below.
Evidence-based anti-MM therapies such as curcumin, whole-body hyperthermia and exercise are also forms of metronomic therapy that can work synergistically with Revlimid and do not cause secondary cancers.
Consider evidence-based but non-toxic therapies that have been shown to enhance the efficacy of Revlimid while reducing it’s toxicity.
Please watch the video below to learn more about the evidence-based, integrative therapies to combat treatment side effects and enhance your chemotherapy.
Consider the idea of metronomic therapies increasing overall survival rather than Revlimid increasing overall survival. Consider integrating curcumin with Revlimid to enhance the efficacy while decreasing toxicity.
I am both a myeloma survivor and myeloma cancer coach. Please scroll down the page and post a question or comment and I will reply to you ASAP.
“How It Works- Lenalidomide is a thalidomide (Thalomid) analog with immunomodulatory, antiangiogenic, and antineoplastic properties. It inhibits proliferation and induces apoptosis of certain hematopoietic tumor cells, including mantle cell lymphoma, multiple myeloma, and del(5q) myelodysplastic syndrome in vitro and delays tumor growth in hematopoietic tumor models including multiple myeloma…
The combination of lenalidomide and dexamethasone synergizes the inhibition of cell proliferation and the induction of apoptosis in multiple myeloma cells…
The most common adverse events of any grade across both maintenance studies (> 20% of lenalidomide patients) were neutropenia, thrombocytopenia, leukopenia, anemia, upper respiratory tract infection, bronchitis, nasopharyngitis, cough, gastroenteritis, diarrhea, rash, fatigue, asthenia, muscle spasm, and pyrexia. The most common grade 3 or 4 adverse events in the two studies (vs placebo) included neutropenia (59% vs 33% and 54% vs 8%), thrombocytopenia (38% vs 30% and 13% vs 3%), and leukopenia (20% vs 10% and 24% vs 2%).
Serious adverse events occurring in > 4.5% of lenalidomide patients were lung infection and neutropenia. The most common adverse events leading to discontinuation of lenalidomide were thrombocytopenia (2.7%) and neutropenia (2.4%).
In patients receiving lenalidomide maintenance therapy following high-dose intravenous melphalan and autologous stem cell transplant, hematologic second primary malignancies occurred in 7.5% of patients compared to 3.3% of patients receiving placebo…”
“Toxic effects and chemoresistance are major hurdles in chemotherapy and to avoid these problems caused by traditional chemotherapeutic regimens, a new modality of drug administration called “metronomic chemotherapy” has emerged. Such regimen involves the frequent administration of conventional chemotherapeutic agents at very low doses to target activated endothelial cells in tumors, the advantages of which include minimal adverse effects and a rare chance of developing acquired drug resistance. Previously it was thought that they act by targeting angiogenesis, but recently additional mechanisms have been discovered which has established metronomic chemotherapy as a type of multi-targeted therapy…”
“Conclusion: Curcumin exerts a cytotoxic effect additive to that of lenalidomide on H929 myeloma cells, and it also enhances the chemo-sensitizing effects of this agent…”